Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026)
Ribociclib plus letrozole met the primary end point, achieving meaningful response rates and durable disease control in recurrent LGSOC. The safety profile was consistent with prior CDK4/6 inhibitor studies. This combination represents a therapeutic option in this rare and genomically distinct subtype.
Authors
- Lee-may Chen (ORCID: https://orcid.org/0000-0003-3370-0161)
- Floor Jenniskens Backes (ORCID: https://orcid.org/0000-0002-9225-6913)
- Robert Louis Coleman (ORCID: https://orcid.org/0000-0001-9343-8754)
- Vivek Podder (ORCID: https://orcid.org/0000-0003-3103-3043)
- Mitchell I. Edelson (ORCID: https://orcid.org/0000-0001-6708-7380)
- David M. Gershenson (ORCID: https://orcid.org/0000-0001-9712-2140)
- Laura L. Holman (ORCID: https://orcid.org/0000-0003-1580-5381)
- David M. O’Malley (ORCID: https://orcid.org/0000-0002-2828-0177)
- J. Rebecca Liu
- Elena Diaz Moore
- Merry Jennifer Markham (ORCID: https://orcid.org/0000-0003-3567-3494)
- Shannon N. Westin (ORCID: https://orcid.org/0000-0002-1922-0156)
- Jayanthi Lea (ORCID: https://orcid.org/0000-0002-8657-4309)
- Eleonora Teplinsky (ORCID: https://orcid.org/0000-0001-8179-6079)
- Eric D. Thomas (ORCID: https://orcid.org/0000-0003-4300-2893)
- Wei Deng (ORCID: https://orcid.org/0000-0003-1778-2013)
- David Scott Miller (ORCID: https://orcid.org/0000-0002-8215-5887)
- Brian M. Slomovitz (ORCID: https://orcid.org/0000-0002-7241-3096)
- Michael J. Callahan (ORCID: https://orcid.org/0000-0002-7833-4524)
- William H. Rodgers (ORCID: https://orcid.org/0000-0003-3946-3136)
- Grace M. Choong (ORCID: https://orcid.org/0000-0002-9668-6072)
- Martina Murphy
- Michael S. Guy (ORCID: https://orcid.org/0000-0001-6752-8959)
- Larry J. Copeland (ORCID: https://orcid.org/0000-0001-6204-0962)
- S. John Weroha (ORCID: https://orcid.org/0000-0002-7130-7259)
- Edwin Alvarez (ORCID: https://orcid.org/0000-0002-9121-0833)
- Jing‐Yi Chern (ORCID: https://orcid.org/0000-0003-0331-9941)
- Thomas J. Herzog (ORCID: https://orcid.org/0000-0002-4584-8908)
- Aparna A. Kamat
- Carolyn Y. Muller
- Hye Sook Chon
- Meaghan Tenney (ORCID: https://orcid.org/0009-0000-1336-096X)
Institutions
- Northside Hospital (US)
- Roswell Park Comprehensive Cancer Center (US)
- Trinity Health (US)
- NorthShore University HealthSystem (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of New Mexico (US)
- University of California, San Francisco (US)
- Thomas Jefferson University Hospital (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- Texas Oncology (US)
- University of Florida Health (US)
- New York Hospital Queens (US)
- Saint Vincent Health System (US)
- Miami Valley Hospital South (US)
- Moffitt Cancer Center (US)
- Mount Sinai Medical Center (US)
- Valley Health System (US)
- St. Vincent Hospital (US)
- Oklahoma Cancer Specialists and Research Institute (US)
- Sidney Kimmel Cancer Center (US)
- Mayo Clinic in Arizona (US)
- Houston Methodist Sugar Land Hospital (US)
- New Mexico Cancer Center (US)
- Jefferson Hospital (US)
- The US Oncology Network (US)
- UNM Comprehensive Cancer Center
- University of Oklahoma Health Sciences Center (US)
- The Ohio State University (US)
- University of Cincinnati (US)
- The University of Texas Southwestern Medical Center (US)
- Florida College (US)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2025-12-12
- DOI
- https://doi.org/10.1200/jco-25-01348
- Citations
- 2
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 3.04